Adjuvant therapies to antifibrotic therapy in IPF. Importance of multidisciplinary management

##plugins.themes.bootstrap3.article.sidebar##

PDF (Español (España)) Crossref (Español (España))
Published Jan 9, 2020

##plugins.themes.bootstrap3.article.main##

Álvaro Undurraga P.
Profesor Adjunto Universidad de Chile. Instituto Nacional del Tórax, Clínica Las Condes. Santiago
Felipe Reyes C.
Coordinador Comisión de Enfermedades Pulmonares Intersticiales Difusas, SER Chile. Hospital Clínico U niversidad de Chile. Instructor Universidad de Chile. Santiago
José Luis Velásquez M.
Hospital San Juan de Dios. Clínica Hospital del Profesor. Docente Universidad San Sebastián. Santiago, Chile
Claudia Azócar B.
Jefe Sección Enfermedades Respiratorias, Departamento de Medicina Interna, Universidad de Concepción. Clínica Universitaria de Concepción. Concepción
Hernán Cabello A.
Clínica Alemana de Santiago. Santiago
Miguel Aguayo C.
Hospital Guillermo Grant Benavente, Concepción. Profesor asistente Universidad de Concepción.
Manuel Vargas D.
Sala ERA, Hospital E. Torres G. Iquique
Daniela Maturana S.
Hospital Clínico Dra. Eloísa Díaz, La Florida. Santiago
Daniela Díaz H.
Clínica BUPA (British United Provident Association) Santiago

Abstract

Idiopathic pulmonary fibrosis (IPF) is characterized by reduced functional capacity, dyspnea and exercise-induced hypoxia, which decreases tolerance to exertion and limits the ability to perform daily activities. Comorbidities are frequent and their presence contribute to worsening quality of life and increased mortality. Therefore, in addition to antifibrotic therapies, patients with IPF benefit of a comprehensive approach to care that may include: screening, diagnosis and treatment of comorbidities, admission to research protocols, symptomatic management, palliative care, supplementary oxygen, pulmonary rehabilitation, education and support by a multidisciplinary team.

##plugins.themes.bootstrap3.article.details##

Keywords.

Idiopathic Pulmonary Fibrosis, Comorbidity, Quality of Life, Palliative Care, Oxygen, Patient Care Team

Issue
Vol. 35 No. 4 (2019): Chilean clinical practice guidelines for idiopathic pulmonary fibrosis, 2019
Section
Artícules
Copyright.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

Undurraga P., Álvaro, Reyes C., F., Velásquez M., J. L., Azócar B., C., Cabello A., H., Aguayo C., M., Vargas D., M., Maturana S., D., & Díaz H., D. (2020). Adjuvant therapies to antifibrotic therapy in IPF. Importance of multidisciplinary management. Revista Chilena De Enfermedades Respiratorias, 35(4), 293–303. Retrieved from https://revchilenfermrespir.cl/index.php/RChER/article/view/862

Most read articles by the same author(s)

1 2 > >>